Dynavax Reports Interim Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck

World News: . []

BERKELEY, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced data from its ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® , an anti-PD-1 therapy developed by Merck (known as MSD outside the United States and Canada). These data were presented in a poster session at the 2018 American Association for Cancer Research (AACR) Annual Meeting.  The results from this dose escalation study showed encouraging response rates in patients with advanced head and neck squamous cell carcinoma. In addition, the combination was well tolerated. The full poster presentation can be accessed at .

“Results from our Phase 1b/2 trial of SD-101 in combination with KEYTRUDA are promising in head and neck cancer, a condition for which patients typically have a poor prognosis,” said Eddie Gray, Chief Executive Officer of Dynavax. “This is another tumor type in which SD-101, based on early data, has demonstrated encouraging activity while being well tolerated. As understanding of combination therapy matures we believe an effective immune stimulating agonist with an attractive tolerability profile will play a significant role in a wide range of tumors.”  

“On Tuesday, April 17, 2018 we are also presenting updated data from our Phase1b/2 study at AACR from a cohort of melanoma patients, where a durable response was observed in patients naïve to anti-PD-1/L1 therapy as well as patients with prior treatment. We are excited about the overall results to date and believe this underscores the potential breadth of our immuno-oncology platform,” Mr. Gray added.

Details for the poster presentation are as follows:

Session Title: Phase I Trials in ProgressAbstract: CT139Poster Board Number: 22Date/Time: Tuesday Apr 17, 2018 8:00 AM - 12:00 PM CDTLocation: McCormick Place South, Hall A, Poster Section 42

SD-101 in combination with KEYTRUDA generally was well tolerated. The most common treatment-emergent adverse events were injection site reactions and transient grade 1 to 2 flu-like symptoms, including fever, chills and myalgia.

KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

David BurkeDirector, Investor Relations & Corporate Communications510.665.7269 

More news and information about Dynavax Technologies Corporation

Published By:

Globe Newswire: 19:10 GMT Monday 16th April 2018

Published: .

Search for other references to "dynavax" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us
 

Advertising on SPi News: Information For Advertisers